Munir Pirmohamed

Professor Sir Munir Pirmohamed is a clinical pharmacologist, geneticist and the NHS Chair of Pharmacogenetics.

Background

Munir Pirmohamed studied Medicine at the University of Liverpool from 1980 to 1985,^[1] Professor Pirmohamed then went on to study a PhD in Pharmacology in 1993, and began working as a Consultant Physician at the Royal Liverpool University Hospital in 1996.^[2] Professor Pirmohamed gained the position of Personal Chair in Clinical Pharmacology at The University of Liverpool in 2001, and went on to become the NHS Chair of Pharmacogenetics in 2007. Professor Pirmohamed is a member of the Commission on Human Medicines and Chair of its Pharmacovigilance Expert Advisory Group, in addition to the role of Deputy Director for the MRC Centre for Drug Safety Sciences in Liverpool. Alongside these responsibilities Professor Pirmohamed also sits on the advisory board for precision medicine company Geneix.

Research

Pharmacogenetics and drug safety are the main areas of Professor Pirmohamed's research. With a particular focus on adverse drug reactions, their role in improving prescription choices and the development of genetic tests for personalised medicine.

Awards

Professor Pirmohamed has received the William Withering Medal from the Royal College of Physicians and the IPIT award for Public Service from the University of North Carolina in the US.^[3] Awarded a knighthood in Queen's birthday honors in June 2015 for services to Medicine.

Professional memberships

• British Medical Association
• Association of Physicians
• Medical Council on Alcohol
• Medical Research Society
• Fellowship of Postgraduate Medicine

Funding

Professor Pirmohamed has been awarded funding from The UK Department of Health, NIHR, MRC, Wellcome Trust, Wolfson Foundation, and the EU FP7 programme funds .^[4]

Publications

• Metabolism and bioactivation of clozapine by human liver in vitro^[5]
• Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis^[6]
• Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.^[7]
• Anticipating, investigating and managing the adverse effects of drugs^[8]
• TNF-alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients^[9]
• Are chemically reactive metabolites responsible for adverse reactions to drugs?^[10]
• TNF-alpha promoter region gene polymorphisms in HIV-positive subjects with lipodystrophy^[11]
• Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro^[12]
• Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes^[13]
• A method for the rapid depletion of albumin and immunoglobulin from human plasma^[14]
• Active Transport Of Imatinib Into And Out Of Cells: Implications For Drug Resistance^[15]
• Whole blood cultures from renal transplant patients stimulated ex-vivo show that the effects of cyclosporin on lymphocyte proliferation are related to P-glycoprotein expression^[16]
• Active transport of imatinib into and out of cells: implications for drug resistance^[15]
• Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity^[17]
• Whole blood cultures from renal transplant patients stimulated ex-vivo show that the effects of cyclosporin on lymphocyte proliferation are related to P-glycoprotein expression^[16]
• Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients^[18]
• The role of metabolic activation in drug-induced hepatotoxicity^[19]
• Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver^[20]
• Characterization of the T-cell response in a patient with phenindione hypersensitivity^[21]
• Carbamazepine-induced acute liver failure as part of the DRESS syndrome^[22]
• hOCT 1 and resistance to imatinib^[23]
• Drug presentation to T cells^[24]
• Characterization of the T-cell response in a patient with phenindione hypersensitivity^[21]
• Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors^[25]
• Investigation of toxic metabolites during drug development^[26]
• Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens^[27]
• How do NHS general hospitals in England deal with patients with alcohol-related problems? A questionnaire survey^[28]
• The quality of information on monitoring for haematological adverse drug reactions^[29]
• The pharmacogenetics of HIV therapy^[30]
• Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study^[31]
• Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements^[32]
• Clinical practice. Antibiotic allergy^[33]
• Pharmacogenetics in clinical practice: considerations for testing^[34]
• Beyond registration—measuring the public-health potential of new treatments for malaria in Africa^[35]
• Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan^[36]
• Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster^[37]
• Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling^[38]
• Warfarin: almost 60 years old and still causing problems^[39]
• Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance^[40]
• Activation of T-cells by carbamazepine and carbamazepine metabolites^[41]
• The future prospects of pharmacogenetics in oral anticoagulation therapy^[42]
• Genetic factors in the predisposition to drug-induced hypersensitivity reactions^[43]
• The HLA B locus in Caucasians patients with carbamazepine hypersensitivity^[44]
• Adverse drug reactions in hospital in-patients: A pilot study^[45]
• Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis^[46]
• Generation and characterization of antigen-specific CD4(+), CD8(+), and CD4(+)CD8(+) T-cell clones from patients with carbamazopine hypersensitivity^[47]
• Herbal medicines and acute medical emergency admissions to hospital^[48]
• Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity^[49]
• Immunological principles of T-cell-mediated adverse drug reactions in skin^[50]
• Folate Augmentation of Treatment - Evaluation for Depression (FolATED): protocol of a randomised controlled trial^[51]
• Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling^[38]
• Genetics of epilepsy: epilepsy research foundation workshop report^[52]
• Tacrine-induced liver damage: an analysis of 19 candidate genes^[53]

References